Lord's Mark Advances AI-Powered Breast Cancer Screening to Final Clinical Trials
Lord's Mark Industries, in collaboration with C-MET, is advancing its AI-powered, radiation-free wearable breast cancer screening technology to final clinical trials across the USA, Great Britain, and Europe. Developed with high-precision thermal sensors and AI-driven temperature mapping, the technology aims for 98% accuracy in detecting cancer at the cell level. Phase 2 trials will begin in January 2027 in multiple countries. The technology has completed initial trials in India, showing promising results, and has attracted interest from medical device companies amid growing global breast cancer cases.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 42/100.
Outlets measured: thetribune, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 23 Sept, 04:37 am. Other outlets followed.